|
Judicial Watch Files Supreme
Court Brief in Battle to Protect Pregnant Mothers from Abortion Drug
Judicial Watch recently filed an amicus
(friend of the court) brief with the United States Court regarding the
abortion drug Mifeprex
(Mifepristone, formerly known as RU-486).
We argue that “the FDA violated its own unambiguous regulation:”
The judiciary’s default position of bestowing undue deference on
federal agencies has led to the rise of an unelected fourth branch of
government that touches every aspect of our lives. These federal agencies
wield budgets in the hundreds of billions of dollars with little to no
oversight….
In 2000, the FDA harnessed the executive
power from a political administration with a personal agenda bent on
approving the drug mifepristone (“Mifeprex”), which intentionally ends
the life of a prenatal human. In approving Mifeprex, the FDA violated its
own unambiguous regulation and relied on pretext…. The FDA’s actions in
2016 and 2021 were arbitrary and capricious and violated the Administrative
Procedures Act (“APA”).
***
[T]he FDA significantly revised the Mifeprex labeling and REMS [risk
evaluation and mitigation strategy] in 2016 and reduced the safety
requirements. These changes included significantly altered dosage, removal
of the follow-up medical visit, removal of the requirement to take the drug
in a doctor’s office, and expansion of the use through 70 days gestation.
Also of significance and concern, the FDA modified the REMS to require
reporting of only deaths attributable to the drug. No longer would
hospitalizations, transfusions, or other serious adverse events need to be
reported.
The FDA’s asserted rationalization for
these significant changes was that it was “following the science.” The
FDA has not, however, provided the science it followed that could
reasonably explain the changes.
***
In 2021, using the COVID-19 pandemic as a tool, abortion proponents, led
by the American College of Obstetricians and Gynecologists (“ACOG”),
sued the FDA to dispense with the REMS in-person medical visit as a
prerequisite for obtaining Mifeprex and permit the drug to be mailed.
Through a FOIA lawsuit we recently uncovered at least
six Mifeprex-related deaths between 2000 to 2002 that were detailed in
Health and Human Services records.
Make no mistake, this is a dangerous drug. We have known since its
inception that the abortion drug Mifeprex is potentially dangerous to the
mothers as well as the intended victims, the unborn babies. Extremist
abortion politics in the Clinton, Obama and now Biden administration are
putting pregnant mothers at risk. Let’s hope the Supreme Court recognizes
that an extremist abortion agenda has overcome the rule of law at the
FDA.
The Supreme Court
heard oral arguments on
the abortion pill controversy on March 26.
Records produced to us in September 2023 also included an “Annual Report for
Mifepristone,” covering the period September 28, 2000, to
September 27, 2001, produced by the Population Council/Danco Laboratories,
LLC. The summary indicated that during the testing period 32 “adverse
events were reported to Danco and reported by Danco to FDA in periodic
reports.” (The existence of adverse event reports does not necessarily
establish causation.)
Of the 32 reported adverse events, two were 15-day reports (the others
were not serious and/or not unexpected). One of the 15-day reports was
reported as “hemorrhage due to a ruptured ectopic pregnancy and
death.” [Emphasis added] The other was reported as “post
abortal parametritis/endometritis, adult respiratory distress syndrome and
bilateral pneumonia.” This latter 15-day report and one case where fever
was reported represent the total reports on the marketed drug suggesting
infection. In addition, one infection was reported in the Population
Council's 200 mifepristone study and one death [Emphasis
added] due to clostridium sordellii infection was reported in the Canadian
study.
A post-marketing study dated
September 28, 2001, titled “Comparison of abortions induced by
mifepristone followed by vaginal versus oral misoprostol up to 56 days
gestation,” reported on the “safety results” for 940 women. One
person required a blood transfusion, two required administration of
intravenous fluids, one required hospitalization, and one
died. [Emphasis added] The study reported an overall “success”
rate of 97.8 percent.
A September 27, 2002, report on
mifepristone indicated that in a study of 971 women administered a
combination of mifepristone and misoprostol to induce abortions, one
subject needed a blood transfusion, two were administered IV fluids, one
was hospitalized, and one died. [Emphasis added]
In an April 19, 2002, “Dear Health Care Provider” letter from Danco
Laboratories, in a section titled “New Safety Information,” the company
noted:
We have received a small number of reports of ruptured ectopic
pregnancies (including one death [Emphasis added] from
hemorrhage due to a ruptured ectopic pregnancy). As you will recall,
Mifeprex* and misoprostol are not an effective treatment of ectopic
pregnancy. Confirmed or suspected ectopic pregnancy is a contraindication
for the use of Mifeprex and should be ruled out prior to initiating
Mifeprex treatment. Because ectopic pregnancy may be present despite your
best efforts to rule it out before starting Mifeprex treatment, you should
be mindful of the possibility of an ectopic pregnancy throughout the
treatment period and have a plan for its management.
***
Two cases of serious systemic bacterial infection (one
fatal) [Emphasis added] following treatment with Mifeprex and
misoprostol have been reported.
***
We have also received a report of a myocardial infarction [heart attack]
occurring in a 21-year-old woman three days following use of Mifeprex and
misoprostol.
A periodic safety update for
mifepristone under the brand name Mifegyne that was conducted by Exelgyn
Laboratory for the period June 1, 2001, to May 31, 2002, reports:
[T]he Medical Department of Exelgyn recorded from health professionals
and authorities 23 spontaneous reports (of which 12 cases of
serious adverse events, 11 non serious events and no case from
clinical trials) in association with Mifepristone.” [Emphases
in original]
The 12 cases of serious events reported
during the period of review are classified as follows:
3 serious unlabeled. In which 1 case of unintended pregnancy with fetal
malformation, 1 case of death [Emphasis added] and 1 case of
thoracic pain (ischaemic accident).
9 serious labeled with 5 cases of unintended
pregnancy, 2 cases of allergic reaction, 1 excessive bleeding and 1
septicaemia to Streptococcus.
These revelations came on the heels of an August 16,, 2023,
decision by the
U.S. Court of Appeals for the Fifth Circuit, in which the Court was asked
to consider whether the FDA “overlooked important safety risks in
approving mifepristone and amending its restrictions.” The Appeals Court
held:
In loosening mifepristone’s safety restrictions, FDA failed to address
several important concerns about whether the drug would be safe for the
women who use it. It failed to consider the cumulative effect of removing
several important safeguards at the same time. It failed to consider
whether those “major” and “interrelated” changes might alter the
risk profile, such that the agency should continue to mandate reporting of
non-fatal adverse events. And it failed to gather evidence that
affirmatively showed that mifepristone could be used safely without being
prescribed and dispensed in person.
In February 2023, we filed an amicus
curiae (friend of the court) brief in support of Texas-based
Alliance for Hippocratic Medicine (AHM) in its lawsuit against the FDA over
its approval of Mifeprex/Mifepristone. In its brief, Judicial Watch
described the FDA’s approval process as “arbitrary, capricious, an
abuse of discretion and not in accordance with the law.”
In April 2023, U.S. District Judge Matthew Kacsmaryk in Amarillo, Texas
suspended approval
of Mifepristone, which essentially made sales of the abortion pill illegal
in the United States while the Biden Administration’s legal challenge of
the court’s ruling proceeded. Subsequently, the Supreme Court granted
emergency requests by the Justice Department and the pill's
manufacturer Danco Laboratories to put the District Court’s suspension
order on hold while litigation continues.
In October 2007, we reported on our court victory that forced the FDA to
release records about the
abortion drug, which included confirmation that the drug was being
manufactured in China.
In May 2006, we released a Special Report,
containing records that shed light on the Clinton administration’s
aggressive drive to push RU-486 to market in the United States. We obtained
the documents from the National Archives at the Clinton Presidential
Library in Little Rock, Arkansas, in February 2006, shortly after the
archives allowed public access to Bill Clinton’s presidential papers.
The Supreme Court is now considering the issue after oral arguments this
week. A ruling is expected by June.
Federal Court Hears Judicial Watch Challengeto Illinois Counting Ballots
Fourteen Days after Election Day!
Oral argument was
held this week in the U.S. Court of Appeals for the Seventh Circuit
in the case filed on behalf of Congressman Mike Bost and two other
registered Illinois voters to prevent state election officials from
extending Election Day for 14 days beyond the date established by federal
law (Rep. Michael J. Bost,
Laura Pollastrini, and Susan Sweeney v. The Illinois State Board of
Elections and Bernadette Matthews (No. 1:22-cv-02754,
23-2644)).
Our lawsuit was filed on May 25,
2022.
In October 2022, Judge John F. Kness rejected a motion
by Democratic Party of Illinois to intervene as a defendant in our lawsuit. In July
2023 Kness dismissed the case based upon lack of “standing.”
We’re now appealing.
Federal law defines Election Day as the first Tuesday after the first
Monday in November of every even-numbered year. The initial complaint
states: “Despite Congress’ clear statement regarding a single national
Election Day, Illinois has expanded Election Day by extending by 14 days
the date for receipt and counting of vote-by-mail ballots.”
We point out to the
Appeals Court that Illinois election law allows vote-by-mail ballots
received up to 14 days after the polls close on Election Day to be counted
as if they were cast and received on or before Election Day. Illinois law
also provides that “[e]ven vote-by-mail ballots without postmarks shall
be counted if received up to 14 calendar days after Election Day if the
ballots are dated on or before Election Day.”
Our brief also notes:
Plaintiffs allege that all ballots received after Election Day
pursuant to the Illinois Receipt Deadline are illegal and invalid. These
ballots are as invalid as if they were received one year after Election
Day, because they violate the federal Election Day statutes. [Emphasis in
original]
We argue that holding voting open for 14 days past Election Day violates
the constitutional rights of voters and candidates:
Plaintiffs allege three claims. First, they claim Defendants’ receipt
and counting of late, illegal ballots dilutes the value of Plaintiffs’
lawfully cast votes, thereby infringing on their right to vote under the
First and Fourteenth Amendments ... Second, Plaintiffs claim the Receipt
Deadline injures them as federal candidates, infringing on their right to
stand for office under the First and Fourteenth Amendments ... Third,
Plaintiffs claim the [14-day extension] violates their federal statutory
rights …
We explain:
The Board … advised that the number of ballots received after Election
Day through November 17, 2020, could materially affect the unofficial
election results.
***
[Illinois’ own data indicates that] Illinois received as many as
266,417 ballots during the period between November 3 (Election Day) and
November 17, 2020 (Receipt Deadline) …. This tranche of ballots totaled
as much as 4.4% of the total ballots cast in the 2020 election. The record
includes unrebutted, contemporaneous statements by Defendants that this
tranche could change electoral outcomes after Election Day.
***
By counting untimely and illegal ballots received after Election Day and
diluting Plaintiffs’ timely cast and received ballots, Defendants … are
depriving Plaintiffs of rights protected under the First Amendment and 14th
Amendment” and 42 U.S.C. § 1983.
Judicial Watch also separately just sued Illinois to
force the state to clean up its voter rolls, as federal law requires.
Christine Svenson, Esq., of Svenson Law Offices in Palatine, Illinois, is
assisting us with the lawsuit.
(We also have a new lawsuit against
Mississippi, which like Illinois, also counts ballots that arrive days
after Election Day.)
Biden Justice Department Launches Gun Control Resource Center over
Weekend to Avoid Scrutiny
The Left knows gun control isn’t popular with the American people so they
often try to hide their anti-Second Amendment agenda, as our Corruption
Chronicles blog reports.
In an apparent effort to fly under the radar, the Biden administration
strategically launched a controversial gun control initiative that is
receiving millions of taxpayer dollars on a Saturday instead of a weekday
when it is more likely to receive news coverage and social media scrutiny.
The program is called National Extreme Risk
Protection Order (ERPO) Resource Center and it will train a broad range
of the population—law enforcement officials, prosecutors, attorneys,
judges, clinicians, social service providers, behavioral health
professionals and community organizations—to help keep guns out of the
hands of people who pose a threat to themselves or others. It will function
under the Department of Justice (DOJ), which has dedicated millions of
dollars to get it going. The investment demonstrates the DOJ’s commitment
to addressing the gun violence crisis in the United States, according to an
agency official quoted in the weekend announcement.
Biden Attorney General Merrick B. Garland
claims the multi-million-dollar initiative will provide partners across the
country with valuable resources to keep firearms out of the hands of
individuals who pose a threat to themselves or others, a key phrase
repeatedly used throughout program documents. “The establishment of the
Center is the latest example of the Justice Department’s work to use
every tool provided by the landmark Bipartisan Safer Communities Act to
protect communities from gun violence,” Garland said. ERPO laws are
modeled after domestic violence protection orders and create a civil
process that allows police, family, medical professionals, and others to
petition a court to temporarily prohibit someone at risk of harming
themselves or others from purchasing and possessing firearms for the
duration of the order. Assistant Attorney General Amy L. Solomon asserts
that the nation’s gun “crisis” cannot be solved at one level of
government and therefore there must be a collaboration of federal, state,
local and holistic solutions to keep American communities safe.
Judicial Watch has filed a Freedom of
Information Act (FOIA) request with the DOJ’s Office of Justice Programs
(OJP) to uncover records involving the millions in ERPO grants that have
been doled out by the agency, including solicitations, requests for
proposals, contracts, memoranda, work plans, budgets, purchase orders,
meeting minutes, audits and other correspondence. The American public
deserves to know what, if any, politically connected entities received
taxpayer money to conduct the mission of this questionable gun control
program largely crafted in secret. Specifically, Judicial Watch is seeking
records for three ERPO grants and the umbrella Biden administration
endeavor known as Byrne State Crisis Intervention program that funds the
creation and implementation of gun violence reduction initiatives in states
around the nation and has distributed over $238
million in the last two years.
An ERPO program called Firearm Crisis
Intervention Training and Technical Assistance Initiative has received the
largest chunk of money, a total of three awards for $4
million, and Judicial Watch is seeking
records that could shed more light on the award process and how the money
is spent. The program claims to provide expert guidance, training, and
technical assistance to state, local and tribal judges and courts in
support of coordinated and effective state crisis intervention court
proceedings and related gun violence reduction initiatives. A mystery
“advisory committee” provides expertise on assessing and responding to
individuals who may pose a risk to themselves or others with a firearm and
develops training for court staff and judicial officers regarding firearms
laws and best practice as they apply to individuals in crisis. The secret
committee also develops and disseminates a “Judicial Toolkit” on
firearms and crisis intervention, among other things.
The other two projects funded under the
administration’s ERPO initiative and listed in Judicial Watch’s FOIA
request are called Implementing Safer Communities Training and Technical
Assistance and the John Hopkins ERPO Resource Center (ERC): Maximizing
Impact Through Evidence, Equity, and Implementation, which have received $1
million and $2 million respectively. The first aims to advance data
collection to help develop and administer tools to ascertain crisis
intervention gaps and needs. The second is hub based at a private
university in Maryland designed to support states and localities with the
implementation of programs to reduce gun violence by providing research,
technical assistance and other educational materials.
Happy Easter!
“The great gift of Easter is hope.” - Basil Hume
Christians around the world are celebrating the resurrection of the Christ
this Easter. There are no more powerful symbols of hope than the cross and
the empty tomb. From me and mine, I wish you and yours all the joy of
Easter!
Until next week,
|
|
|
|
|
|
|
|
|
Judicial Watch, Inc.
425 3rd St Sw Ste 800
Washington, DC 20024
|
|
202.646.5172 |
|
|
© 2017 - 2024, All Rights Reserved
Manage
Email Subscriptions |
Unsubscribe |
|
|
|
|
|
|
|
|